Physician profile
Sumathi S Smith
NPI 1932189016
$1,983.25
in general payments reported to CMS, 2019-2025
34 companies · $274 in 2025
The $274 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $362 · 2021: $146 · 2022: $511 · 2023: $260 · 2024: $431 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $964.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $964.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $428.40 | 2019-2025 | Keytruda, Lynparza |
| Janssen Biotech, INC. | $170.67 | 2022 | |
| Daiichi Sankyo INC. | $134.14 | 2023-2025 | Enhertu, Datroway |
| Ethicon INC. | $133.16 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.84 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $107.24 | 2022-2025 | Enhertu, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $103.48 | 2019-2025 | Opdivo, Opdualag |
| Novartis Pharmaceuticals Corporation | $92.07 | 2022-2025 | |
| Eisai INC. | $71.95 | 2022 | |
| Gilead Sciences, INC. | $47.08 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.68 | 2023-2024 | Alunbrig |
| Mirati Therapeutics, INC. | $41.20 | 2023 | Krazati |
| Abbvie INC. | $39.44 | 2025 | |
| Jazz Pharmaceuticals INC. | $34.77 | 2025 | |
| Lilly USA, LLC | $32.60 | 2019-2023 | Jaypirca, Verzenio |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $30.67 | 2019-2025 | Reblozyl |
| Genzyme Corporation | $27.37 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $26.06 | 2019 | |
| Genentech USA, INC. | $24.09 | 2025 | Venclexta |
| Exelixis INC. | $22.79 | 2022 | |
| Pfizer INC. | $22.76 | 2025 | |
| Alexion Pharmaceuticals, INC. | $22.70 | 2024 | Ultomiris |
| Veracyte, INC. | $21.77 | 2023 | |
| Amgen INC. | $18.95 | 2023 | Lumakras |
| Tempus Ai, INC | $18.24 | 2024 | |
| Myovant Sciences INC. | $17.13 | 2022 | |
| Cti Biopharma Corp. | $16.86 | 2023 | Vonjo |
| Incyte Corporation | $16.50 | 2024 | Jakafi |
| Beigene USA, INC. | $16.33 | 2022 | |
| Blueprint Medicines Corporation | $16.19 | 2022 | |
| Shield Therapeutics INC | $15.59 | 2024 | |
| Apellis Pharmaceuticals, INC. | $15.40 | 2024 | Empaveli |
| Taiho Oncology, INC. | $14.84 | 2019 | |
| Seagen INC. | $13.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumathi Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.